The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin.
 
Chase Allain Shipp
No Relationships to Disclose
 
Tanya Jindal
No Relationships to Disclose
 
Kevin R Reyes
No Relationships to Disclose
 
Xiaolin Zhu
Employment - Exelixis (I)
 
Chien-Kuang Cornelia Ding
No Relationships to Disclose
 
Emily Chan
Research Funding - Ibex (Inst)
 
Bradley A. Stohr
No Relationships to Disclose
 
Prianka Deshmukh
No Relationships to Disclose
 
Kelly N. Fitzgerald
Consulting or Advisory Role - Janssen; MJH Life Sciences
 
Daniel Kwon
No Relationships to Disclose
 
Rohit Bose
Honoraria - Janssen; Qessential Medical Marketing Research; Tegus
 
Arpita Desai
Consulting or Advisory Role - Dendreon; Exelixis; Janssen Oncology; Merck
 
Ivan de Kouchkovsky
Consulting or Advisory Role - Janssen
 
Rahul Raj Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; EcoR1 Capital; Exelixis; Janssen; Jubilant Pharmaceuticals; Merck; Novartis; OncLive.; PCCTC; Pfizer; Tersera
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology
 
Eric J. Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen; Johnson and Johnson
Consulting or Advisory Role - Fortis; Janssen Oncology; Teon Therapeutics
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma
Consulting or Advisory Role - Actym Therapeutics; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; EMD Serono; ImmunoGenesis; Innovent Biologics; Janssen Oncology; Merck; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Sima P. Porten
Honoraria - American Urologic Association; Exact Sciences; Pacific Edge
Consulting or Advisory Role - AstraZeneca; Oncuria; Photocure; Stryker
Research Funding - Photocure (Inst)
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; EMD Serono
Consulting or Advisory Role - AADi; Astellas Pharma; Basilea; Dava Oncology; EMD Serono; Foundation Medicine; Merck; Seagen; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
 
Jonathan Chou
Consulting or Advisory Role - Exai Bio
Research Funding - Amgen (Inst)
 
Vadim S Koshkin
Consulting or Advisory Role - Clovis Oncology; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Seagen (Inst); Taiho Oncology (Inst)